Yahoo Finance

Operations: The company's revenue segment consists of CN¥663.61 million from the sales of neurovascular and peripheral-vascular interventional surgical devices.

Insider Ownership: 19.4%

Zylox-Tonbridge Medical Technology is experiencing substantial growth, with revenue forecasted to increase by 34% annually, significantly outpacing the Hong Kong market's 7.8%. The company became profitable this year and expects earnings to grow at a robust 66.5% annually over the next three years. However, its Return on Equity is projected to remain low at 6.7%. A recent shareholders meeting addressed a Share Award Scheme and Loss Compensation Plan, indicating strategic financial adjustments ahead.

• Unlock comprehensive insights into our analysis of Zylox-Tonbridge Medical Technology stock in this growth report.

• According our valuation report, there's an indication that Zylox-Tonbridge Medical Technology's share price might be on the expensive side.

Tri Chemical Laboratories

Simply Wall St Growth Rating: ★★★★★☆

Overview: Tri Chemical Laboratories Inc. supplies chemical products for semiconductors, coating, optical fibers, solar cells, and compound semiconductors with a market cap of ¥87.77 billion.

Operations: The company's revenue is primarily derived from its High-Purity Chemical Compound Business for Manufacturing Semiconductors, generating ¥16.14 billion.

Insider Ownership: 17.4%

Tri Chemical Laboratories is set for strong growth, with revenue expected to rise by 22.8% annually, surpassing the Japanese market's 4.2%. Earnings are projected to grow significantly at 31.2% per year over the next three years, though Return on Equity might remain modest at 19.8%. The stock trades at a considerable discount of 52.6% below estimated fair value, and analysts predict an 80.8% price increase despite recent share price volatility.

• Delve into the full analysis future growth report here for a deeper understanding of Tri Chemical Laboratories.

• Our comprehensive valuation report raises the possibility that Tri Chemical Laboratories is priced lower than what may be justified by its financials.

Taking Advantage

• Click through to start exploring the rest of the 1509 Fast Growing Companies With High Insider Ownership now.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ENXTAM:PNL SEHK:2190 and TSE:4369.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com